Orforglipron Vs Oral Semaglutide in ACHIEVE-3

Key Takeaways

• Orforglipron demonstrated both noninferiority and superiority to oral semaglutide in reducing HbA1c at 52 weeks in this phase 3 head-to-head trial.
• Body-weight change and safety were assessed alongside glycemic outcomes, with gastrointestinal events and treatment discontinuations reported more frequently with orforglipron.
• ACHIEVE-3 was a randomized, open-label, multinational phase 3 trial in adults with type 2 diabetes inadequately controlled with metformin.

The primary outcome focused on change in HbA1c at 52 weeks, with a noninferiority margin of 0.3%. Orforglipron met noninferiority criteria and demonstrated superiority over semaglutide across dose comparisons, establishing a quantitative efficacy advantage within the trial framework.

This randomized, open-label, multicenter, multinational study enrolled 1698 participants across multiple countries. Adults were assigned to orforglipron 12 mg or 36 mg or semaglutide 7 mg or 14 mg, all administered orally once daily following a short lead-in period. Baseline HbA1c averaged 8.3%, and outcomes were assessed over a 52-week treatment period using intention-to-treat–based estimands.

Mean HbA1c reductions at week 52 were −1.71% with orforglipron 12 mg and −1.91% with orforglipron 36 mg, compared with −1.23% for semaglutide 7 mg and −1.47% for semaglutide 14 mg. Estimated treatment differences favored orforglipron across all comparisons, with statistically significant reductions versus both semaglutide doses. These results satisfied the prespecified noninferiority threshold and supported superiority in hierarchical testing.

Body-weight change was included as a prespecified metabolic outcome, though detailed comparative values were not highlighted in this summary context. The trial overall framed metabolic efficacy across both glycemic and weight domains within a head-to-head oral GLP-1 receptor agonist comparison.

Safety findings were consistent with the GLP-1 receptor agonist class but showed higher rates of gastrointestinal adverse events with orforglipron, occurring in approximately 58% to 59% of participants compared with 37% to 45% with semaglutide. Treatment discontinuations due to adverse events were also more frequent with orforglipron, and mean pulse rate increases were greater. Four deaths occurred during the study, distributed across treatment groups.

The direct oral comparator design remains a defining feature of ACHIEVE-3, enabling within-trial comparison under consistent study conditions. The findings support orforglipron as an effective oral GLP-1 receptor agonist option, while safety differences and tolerability considerations remain part of the overall clinical interpretation.